Navigation Links
New Drug Combination is Able to Eradicate Breast Metastases in Mice
Date:12/17/2007

SAN ANTONIO, Dec. 17 /PRNewswire/ -- A novel combination of drugs was able to completely eradicate human breast metastases growing in mice, and shows promise for the effective treatment of patients with advanced metastatic breast cancer. Dr. Sophia Ran from Southern Illinois University School of Medicine presented the results of a study using nab-paclitaxel and bevacizumab to treat lymphatic and pulmonary metastases in female SCID mice.

Paclitaxel is a widely used cancer chemotherapy drug, originally derived from an extract of the yew tree. It can have severe side effects, some of which are related to the fact that it will not dissolve in water and has to be dissolved in organic solvents for injection. Nab-paclitaxel is a nanoparticle form of paclitaxel that is coated with a nonreactive protein, albumin, allowing it to be dissolved in water. This has reduced the side effects of the treatment, and also makes it more effective.

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A), a protein that is involved in building new blood vessels. Tumors require new networks of blood vessels in order to grow.

The idea for this research came from the observation that, nf cells that survive treatment with chemotherapy, the stress of the treatment causes excess VEGF-A to be produced. The VEGF-A protects the cells against future chemotherapy, and also generates new blood vessels. Both mechanisms may contribute to tumor recurrence and metastatic spread following chemotherapy. This is the molecular basis for combining bevacizumab with nab-paclitaxel for the treatment of metastatic tumors.

For this study, human breast cancer cells were implanted into mammary fat pads (the mouse equivalent of breast tissue) of female mice. The implanted cells grew into tumors, and lymphatic and pulmonary metastases developed by the time that the drugs were administered.

The drug combination completely eradicated the original tumors, although bevacizumab alone had no effect, and nab-paclitaxel alone caused tumor regression for only 27 days, after which the tumors grew back.

The drug combination also completely eradicated metastases in the treated animals. Bevacizumab alone and nab-paclitaxel alone reduced the average number of metastases by no more than 50%.

The combination of bevacizumab and nab-paclitaxel is currently being tested in early trials of women with metastatic breast cancer.


'/>"/>
SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
5. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
7. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
8. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
9. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
10. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
11. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... N.J. , March 27, 2017 Invivotek, ... and leading in vivo pharmacology contract research ... Farm adjacent to its newly expanded preclinical research facility ... solar farm provides a cleaner, renewable energy source to ... the environment. Completion of the Genesis Solar Farm follows ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 Abdominal Aortic ... reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% from 2016 to ... and is projected to dominate the market during the study period. ... ... ...
(Date:3/24/2017)... 24, 2017 New England Pediatric Device Consortium ... award including funding and in-kind service towards the commercialization ... "Making blood draws less traumatic for children ... hospital experience better.  We,re looking forward to working with ... improve care for the kids we treat," said ...
Breaking Medicine Technology:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... quickly sideline athletes. A type of groin injury, it occurs when the muscles ... serious, intense pain in and around the lower torso, as well as accompanying ...
(Date:3/27/2017)... ... 2017 , ... Advantexe Learning Solutions , a global ... new research study, The Business Readiness Report. The report explores the correlation between ... actual success of achieving individual and company goals. , There are many ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... that for a second year in a row; they are the recipient of ... in the industry voted on the award at Design Connections 2017. Top A&D ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
(Date:3/27/2017)... ... 2017 , ... The Anaheim Hills office accelerates and supports FNCC’s growth and ... new sales professionals over the past 6 months and is continuing to recruit new ... the course of 2017. , “This new office is a direct result of ...
Breaking Medicine News(10 mins):